Xtant Medical (NYSEAMERICAN:XTNT) Posts Earnings Results

Xtant Medical (NYSEAMERICAN:XTNTGet Free Report) posted its quarterly earnings results on Wednesday. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, reports. Xtant Medical had a negative net margin of 1.64% and a negative return on equity of 3.60%. The company had revenue of $27.87 million during the quarter.

Xtant Medical Price Performance

Shares of XTNT opened at $0.72 on Friday. Xtant Medical has a 52 week low of $0.60 and a 52 week high of $1.45. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.22 and a current ratio of 2.34.

Institutional Investors Weigh In On Xtant Medical

Several large investors have recently added to or reduced their stakes in the stock. AMH Equity Ltd bought a new position in shares of Xtant Medical during the 3rd quarter valued at about $653,000. AWM Investment Company Inc. acquired a new position in Xtant Medical in the 3rd quarter worth approximately $516,000. Juniper Investment Company LLC acquired a new stake in Xtant Medical during the 1st quarter valued at $408,000. Vanguard Group Inc. lifted its stake in Xtant Medical by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock worth $1,812,000 after acquiring an additional 48,319 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. purchased a new position in Xtant Medical during the third quarter valued at approximately $38,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, BTIG Research upped their target price on shares of Xtant Medical from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Thursday.

Get Our Latest Analysis on Xtant Medical

Xtant Medical Company Profile

(Get Free Report)

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

See Also

Earnings History for Xtant Medical (NYSEAMERICAN:XTNT)

Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.